Harrow, Inc. · NASDAQ:HROW
Harrow — Leerink Partners conference (March 2026)
20 slides from Harrow's conference presentation, Mar 10, 2026
Slide 1: Corporate Presentation – Leerink Partners
Corporate Presentation Leerink Partners >» HARROW Your patients. Our purpose.
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Diversified Ophthalmic Disease Management Solutions
Diversified Ophthalmic Disease Management Solutions Revenue CAGR for the past five years (2020-2025) of 41% Adjusted EBITDA CAGR for the past five years (2020-2025) of 61.3% Key revenue drivers are early Scalable commercial platform Largest U.S. portfolio of prescription ophthalmic in launch phases
Slide 4: Harrow’s Ophthalmic Pharmaceutical Brands
Harrow’s Ophthalmic Pharmaceutical Brands BYQLOVI" (clobetasol propionate mic suspension) 0.05% THEE (lereprcane HC ohitalic g) 3% Flarex’ (Huot ctate ‘ohh suena) L1% Maxidex” (@examethasone phthalic suspension) 0.1% Maxitrol” (neomycin and polymyxin B sutates and dexamethasone ophthalmic suspension
Slide 5: Financials & Outlook
Financials & Outlook Corporate Presentation | March202 HARROW
Slide 6: 2025 Key Financial Metrics
2025 Key Financial Metrics {in thousanas) Consolidated Revenues Adjusted EBITDA $61,923 $272,303 a $28,119 $11,378 $13,017 _ 715 20 21 22 23 24 25 24 25 $72.9 million in cash and cash equivalents as of December 31, 2025 (1) Adjusted EBITDA is defined as net income (oss). exclicing the effects of sto
Slide 7: 2026 Financial Guidance
2026 Financial Guidance Full Year 2026 Outlook H1 H2 Full Year Revenue $133M-$153M $203M-$226M $350M-$365M (midpoint ~$143M) (midpoint ~$21 4.5M) (midpoint ~$357.5M) Full Year Adjusted $80M-$100M EBITDA (midpoint ~$90M) HARROW Corporate Presentation |!
Slide 8: Dry Eye Disease
Dry Eye Disease VEVYE Corporate Presentation | March202e HARROW ™
Slide 9: Dry Eye Disease: Growing Market; Best-in-Class Solution
Dry Eye Disease: Growing Market; Best-in-Class Solution Q4 Highlights The first and only water-free cyclosporine to treat the signs Prescriber Expansion: +115% growth in 20252 and symptoms of dry eye disease Refill Rates: Covered Rx refill avg. ~9 times in 2025! In a pre-clinical ex-vivo corneal pen
Slide 10: Ocular Anesthesia
Ocular Anesthesia Corporate Presentation | March2028 HARROW’
Slide 11: IHEEZO Overview
IHEEZO Overview THEEZO. First approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride —_ a First branded ocular anesthetic approved for the U.S. market in nearly 14 years. Sterile, single-patient-use, . . physician-administered, IHEEZO Reimbursement: ophthalmic gel preparation Per
Slide 12: IHEEZO Q4 2025 Key Metrics
IHEEZO Q4 2025 Key Metrics Year-over-Year Demand Expected to Grow Highlights: » 56% year-over-year unit demand growth » 49% year-over-year account growth? * ~70% of 2025 unit volume driven by retina accounts*® » Improvement in net pricing in effect H2 2026 * 85% customer reorder rate* Priorities * R
Slide 13: IHEEZO: Accelerating Growth
IHEEZO: Accelerating Growth aun Unlocking the Full In-Office Market » Growing retina market share despite the absence of retina- specific clinical data » Office-based expansion (2.5M+ annual procedures) materially increases TAM beyond retina Multi-Unit Packaging » New multi-unit IHEEZO packaging des
Slide 14: Ophthalmic Surgical
Ophthalmic Surgical TRIESENCE G-MELT Product Candidate Corporate Presentation | March202e HARROW ™
Slide 15: TRIESENCE Overview & Q4 2025 Key Highlights
ieience TRIESENCE Overview & Q4 2025 Key Highlights ‘eee 40mgimL Q4 Highlights: Description: Largest quarterly revenue since Q4 2024 re-launch * The only FDA-approved preservative-free synthetic corticosteroid with separate reimbursement in all traditional settings of care Retina use continues to gr
Slide 16: G-MELT: IV- and Opioid-Free Sedation
G-MELT: IV- and Opioid-Free Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form Technology + Powered by Zydis® ODT technology, exclusively licensed from Catalent + Dissolves in seconds under the ton
Slide 17: Rare, Specialty, and Compounded Products
Rare, Specialty, and Compounded Products Corporate Presentation | March202e HARROW ™
Slide 18: Rare, Specialty, and Compounded
Rare, Specialty, and Compounded Potential significant revenue-generating opportunities with 3 products from portfolio: * Coding decision expected in April 2026 + Twore-launches in on-label markets (one supported by new data in Q4 2026; another, in 2H 2026) Specialty Steroids, NSAIDs, and Antihistami
Slide 19: Investment Summary
Investment Summary Durable Revenue Drivers and a 2026-2028 Pipeline Strengthening an Accelerating Growth Profile 62% revenue growth Q4 2025 vs Q4 2024 Coverage win with the largest commercial PBM started on 1/1/26; increase in Rx volumes expected Doubling sales force by the end of Q2 2026 Average of
Slide 20: Harrow – Your patients. Our purpose.
(» HARROW Your patients. Our purpose. 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890 Your patients. Our purpose. Corporate Presentation | March20% HARROW